**LIM only 4 is overexpressed in late stage pancreas cancer**

Jun Yu¹, Kenoki Ohuchida*¹,², Kohei Nakata³, Kazuhiro Mizumoto*¹, Lin Cui¹, Hayato Fujita¹, Hiroshi Yamaguchi⁴, Takuya Egami¹, Hidehisa Kitada¹ and Masao Tanaka¹

Address: ¹Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Integration of Advanced Medicine and Innovative Technology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ³Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan and ⁴Department of Anatomical Pathology, Saitama Medical University International Medical Center, Saitama, Japan

Email: Jun Yu - shun@surg1.med.kyushu-u.ac.jp; Kenoki Ohuchida* - kenoki@surg1.med.kyushu-u.ac.jp; Kohei Nakata - knakata@surg1.med.kyushu-u.ac.jp; Kazuhiro Mizumoto* - mizumoto@surg1.med.kyushu-u.ac.jp; Lin Cui - y2kcl@surg1.med.kyushu-u.ac.jp; Hayato Fujita - hayato@surg1.med.kyushu-u.ac.jp; Hiroshi Yamaguchi - yamhiro@surg1.med.kyushu-u.ac.jp; Takuya Egami - takuya@surg1.med.kyushu-u.ac.jp; Hidehisa Kitada - hide@surg1.med.kyushu-u.ac.jp; Masao Tanaka - masaotan@surg1.med.kyushu-u.ac.jp

* Corresponding authors

**Abstract**

**Background:** LIM-only 4 (LMO4), a member of the LIM-only (LMO) subfamily of LIM domain-containing transcription factors, was initially reported to have an oncogenic role in breast cancer. We hypothesized that LMO4 may be related to pancreatic carcinogenesis as it is in breast carcinogenesis. If so, this could result in a better understanding of tumorigenesis in pancreatic cancer.

**Methods:** We measured LMO4 mRNA levels in cultured cells, pancreatic bulk tissues and microdissected target cells (normal ductal cells; pancreatic intraepithelial neoplasia-1B [PanIN-1B] cells; PanIN-2 cells; invasive ductal carcinoma [IDC] cells; intraductal papillary-mucinous adenoma [IPMA] cells; IPM borderline [IPMB] cells; and invasive and non-invasive IPM carcinoma [IPMC]) by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).

**Results:** 9 of 14 pancreatic cancer cell lines expressed higher levels of LMO4 mRNA than did the human pancreatic ductal epithelial cell line (HPDE). In bulk tissue samples, expression of LMO4 was higher in pancreatic carcinoma than in intraductal papillary-mucinous neoplasm (IPMN) or non-neoplastic pancreas (p < 0.0001 for both). We carried out microdissection-based analyses. IDC cells expressed significantly higher levels of LMO4 than did normal ductal epithelia or PanIN-1B cells (p < 0.001 for both) or PanIN-2 cells (p = 0.014). IPMC cells expressed significantly higher levels of LMO4 than did normal ductal epithelia (p < 0.001), IPMA (p < 0.001) and IPMB cells (p = 0.003).

**Conclusion:** Pancreatic carcinomas (both IDC and IPMC) expressed significantly higher levels of LMO4 mRNA than did normal ductal epithelia, PanIN-1B, PanIN-2, IPMA and IPMB. These results suggested that LMO4 is overexpressed at late stages in carcinogenesis of pancreatic cancer.
**Introduction**

Pancreatic cancer is one of the most aggressive malignant tumors. It is the fifth leading cause of cancer death in Japan [1,2] and has the lowest survival rate of any solid cancer [3]. Because the lack of specific symptoms in patients with pancreatic cancer makes early diagnosis difficult, initial diagnosis typically occurs when the tumor has reached an advanced stage [4]. A better understanding of pancreatic carcinogenesis is urgently needed to facilitate early detection. Pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary-mucinous neoplasm (IPMN) were reported to be precursor lesions of pancreatic cancer [5-8]. Development of invasive ductal adenocarcinoma has been proposed to occur via two pathways [9-11], the PanIN-Invasive ductal carcinoma (IDC) progression pathway and the IPM adenoma (IPMA)-invasive IPM carcinoma (IPMC) pathway, although some specific subtypes of IPMN, such as intestinal-type IPMN, may not progress to invasive carcinoma through the same genetic pathway as PanIN. Longnecker et al [12] reported that PanIN-1 and IPMA showed mild dysplasia (grade 1), PanIN-2 and IPM borderline (IPMB) lesions showed moderate dysplasia (grade 2), and PanIN-3 and IPMC (carcinoma in situ [CIS]) showed severe dysplasia (grade 3).

LIM-only 4 (LMO4) is one of the four members (LMOs 1, 2, 3 and 4) of the LIM-only subfamily of LIM domain proteins. LIM domains are an approximately 55-amino acid, cysteine-rich, zinc-binding motif that mediate protein-protein interactions present in a variety of proteins including LIM homeobox proteins [13]. The nuclear LIM-only proteins (LMOs 1-4) lack a DNA-binding domain but still function as transcriptional regulators by recruiting other protein partners including transcription factors [14,15]. Kenny et al [13] reported the isolation and characterization of LMO4, a novel LIM-only gene that is highly expressed in the T-lymphocyte lineage, cranial neural crest cells, somites, dorsal limb bud mesenchyme, motor neurons and Schwann cell progenitors. As well as its role in development, there are several lines of evidence suggesting that LMO4 may have roles in oncogenesis [16]. LMO4, initially described as a human breast tumor autoantigen [17], was reported to have a role in maintaining proliferation of mammary epithelium and suggested that deregulation of this gene may contribute to breast tumorigenesis [18]. Additionally, Sum et al [19] found that LMO4 interacts with the cofactor CtIP and the tumor suppressor breast cancer 1 (BRCA1), and inhibits the transcriptional activity of BRCA1 in both yeast and mammalian cells by functional assays. They concluded that deregulation of LMO4 in breast epithelium directly contributes to breast neoplasia by altering the rate of cellular proliferation and promoting cell invasion. In 2005, Sum and colleagues reported that LMO4 mRNA was overexpressed in 5 of 10 human breast cancer cell lines; in situ hybridization analysis of 177 primary invasive breast carcinomas revealed overexpression of LMO4 in 56% of the specimens [20]. It has also been reported that expression of LMO4 is up-regulated at the invasive front of oral cancer, suggesting a role in cancer cell invasion [21]. It was recently reported that the bone morphogenetic protein (BMP7) gene, which controls cell proliferation and apoptosis of mammary epithelial cells, is a direct target of LMO4 [22]. Both pancreatic cancer and breast cancer are known to have an epithelial origin while pancreatic cancer also reveals papillo-tubular structures that are similar to the histological characteristics of the initial breast cancer [23]. As well, known genetic changes in pancreatic cancer often involve the same genes as those found in breast cancer [24]. Taken together, these findings suggest that LMO4 has critical functions in pancreatic carcinogenesis as well as in normal development. Thus clarification of the role of LMO4 may be useful for diagnosis and/or treatment of pancreatic cancer. However, little is known about the role of LMO4 in pancreatic cancer and carcinogenesis.

To determine whether LMO4 is correlated with pancreatic cancer and carcinogenesis, we quantified LMO4 mRNA levels in cultured pancreatic cell lines, bulk tissues and microdissection-based target cells (including normal pancreatic ductal, PanIN-1B and PanIN-2, IDC, IPMA, IPMB and IPMC cells), by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). Our goal was to characterize LMO4 expression in the early and late stages of pancreatic carcinogenesis to clarify both if and when overexpression of LMO4 occurs.

**Materials and methods**

**Cultured cells**

Fourteen pancreatic cancer cell lines, AsPC-1, KP-1N, KP-2, KP-3, PANC-1, SUIT-2 (provided by Dr. H. Iguchi, National Shikoku Cancer Center, Matsuyama, Japan), MIA PaCa-2 (Japanese Cancer Resource Bank, Tokyo, Japan), NOR-P1 (established in our laboratory), CAPAN-1, CAPAN-2, CF Pac-1, H48N, HS766T and SW1990 (American Type Culture Collection, Manassas, VA, USA), the HPDE cell line and six primary cultures of fibroblasts derived from pancreatic tumors were studied. Cells were maintained as described previously [25].

**Pancreatic tissues**

Tissue samples were obtained during surgery at Kyushu University Hospital (Fukuoka, Japan) as described previously [26]. In brief, tissue samples were removed and divided into at least three bulk tissue specimens. The first sample was immediately but temporarily preserved in cold PBS and then embedded in OCT compound (Sakura Finde, Tokyo, Japan), snap-frozen for microdissection within 1 hour after resection, and stored at -80°C until
use. The second sample was fixed in formalin, embedded in paraffin and cut into 4-μm-thick sections for hematoxylin and eosin (H&E) staining. The third sample was immediately snap-frozen for bulk tissue analysis and stored at -80°C until use. Tissues adjacent to the specimens were examined histologically and the diagnosis confirmed by two pathologists, Dr Hiroshi Yamaguchi and Dr Kohei Nakata (Figure 1). Written informed consent was obtained from all patients, and the study was approved by our institution’s surveillance committee and conducted according to the Helsinki Declaration.

**RNA isolation**

Total RNA was extracted from cultured cells with a High Pure RNA Isolation Kit (Roche, Mannheim, Germany). Total RNA was extracted from bulk tissues with an RNeasy Mini Kit (Qiagen, Tokyo, Japan) following the manufacturer’s protocol. Total RNA was extracted from cells isolated by microdissection with the standard acid guanidinium thiocyanate-phenol-chloroform protocol [27] with or without glycogen (Funakoshi, Tokyo, Japan) [26].

**Quantitative assessment of LMO4 level by real-time RT-PCR**

Quantitative real-time RT-PCR was performed with a QuantiTect SYBR Green RT-PCR Kit (Qiagen, Tokyo, Japan) with a Chromo4™ System (Bio-Rad, Hercules, CA, USA). In brief, the reaction mixture was first incubated at 50°C for 30 min to allow for reverse transcription. PCR was initiated with one cycle of 95°C for 15 min to activate the modified Taq polymerase followed by 40 cycles of 94°C for 15 sec, 55°C for 20 sec, and 72°C for 10 sec, and one cycle of 95°C for 0 sec, 65°C for 15 sec and +0.1°C/sec to 95°C for melting analysis. Each sample was run in triplicate. The level of LMO4 mRNA expression was calculated from a standard curve constructed with total RNA from the SUIT-2 pancreatic cancer cell line. The range of threshold cycles was from 20–35 cycles for LMO4 primers (forward, 5’-GGA CCG CTT TCT GCT CTA TG-3’; reverse, 5’-AAG GAT CAT GCC ACT TTT GG-3’), and from 7–35 cycles for 18S rRNA primers (forward 5’-GAT ATG CTC ATG TGG TGT TG-3’; reverse, 5’-AAT CTT CTT CAG TCG TCT CA-3’). Expressions of LMO4 mRNA were normalized to that of 18S rRNA.

**Figure 1**

Histologic examination of formalin-fixed, paraffin-embedded (FFPE) samples with hematoxylin and eosin (H&E) staining. The stages of the PanIN-IDC pathway are shown as normal pancreatic ductal epithelia (A), pancreatic intraepithelial neoplasm-1B (PanIN-1B) (B), PanIN-2 (C) and invasive ductal carcinoma (IDC) (D). The stages of the intraductal papillary mucinous adenoma (IPMA)-intraductal papillary mucinous carcinoma (IPMC) pathway are shown as IPM adenoma (E), IPM borderline (F) and IPM carcinoma (G). (Magnifications of A to G are 100×, 100×, 100×, 200×, 100×, 200×, 200×, respectively).
Microdissection-based quantitative analysis of LMO4 mRNA

Frozen tissues were cut into 8-μm-thick sections. IDC cells from 8 lesions, PanIN-2 cells from 3 lesions, PanIN-1B cells from 14 lesions, normal ductal epithelial cells from 13 ducts, IPMA cells from 13 lesions, IPMB cells from 15 lesions, and IPMC cells from 8 lesions, including 3 non-invasive IPMC lesions (CIS) and 5 invasive IPMC lesions, were selectively isolated with a laser microdissection and pressure catapulting system (P.A.L.M. Microlaser Technologies, Bernried, Germany) in accordance with the manufacturer’s protocols (Figure 2) [28]. After microdissection,
total RNA was extracted from the selected cells and subjected to qRT-PCR for quantitative measurement of LMO4 as described previously [26].

Statistical analysis
Data were analyzed with multiple comparison in ANOVA (analysis of variance) and Bivariate Correlations with Statistics Package for Social Science (SPSS) software (SPSS Inc. Chicago, IL, USA) after Kolmogorov-Smirnov test to assure that each data set is showed a normal distribution. For multiple comparisons by ANOVA, we used the least significant difference (LSD) test and set the statistical significance at \( p < 0.05 \). We used Spearman test for bivariate correlations.

Results
Quantitative analysis of LMO4 expression in 14 pancreatic cancer cell lines, a non-neoplastic ductal epithelial cell line and six primary cultures of pancreatic fibroblasts
We investigated LMO4 mRNA expression in 14 pancreatic cancer cell lines, HPDE, a normal pancreatic ductal cell line immortalized by transduction with the E6/E7 genes of human papillomavirus 16 [29,30], and 6 primary cultures of pancreatic fibroblasts derived from resected pancreatic tumors. As shown in Figure 3, 9 of the 14 pancreatic cancer cell lines expressed higher levels of LMO4 than did HPDE. We also found that all 6 primary cultures of pancreatic fibroblasts expressed moderate levels of LMO4. Four pancreatic cancer cell lines, Hs766T, AsPC-1, KP-2 and KP-3, expressed higher levels of LMO4 than did any of the primary cultures of pancreatic fibroblasts. We next examined whether LMO4 expression is related to the origin of these cancer cell lines, but found no correlation between LMO4 expression and site of origin, such as primary or metastatic tumors (Figure 3).

Quantitative analyses of LMO4 expression in bulk pancreatic tissues
In the bulk tissue analyses, we measured LMO4 expression in pancreatic cancer tissues \((n = 11)\), and non-neoplastic tissues \((n = 20)\), normal pancreatic or chronic pancreatitis-related tissues, and non-malignant IPMN tissues \((n = 11)\). As shown in Figure 4, LMO4 expression was highest in the pancreatic cancer tissues with a mean of 0.24 (95% confidence interval [CI], 0.16 – 0.32), whereas the LMO4 expression levels were 0.03 (95% CI, 0.02 – 0.04) in non-neoplastic tissues and 0.08 (95% CI, 0.04 – 0.12) in non-malignant IPMN tissues. The mean LMO4 mRNA level in pancreatic cancer tissues was eight-fold higher than that in non-neoplastic tissues and three-fold higher than that in non-malignant IPMN tissues \((p < 0.0001)\) and three-fold higher than that in non-malignant IPMN tissues \((p < 0.0001)\). The mean LMO4 mRNA level in non-malignant IPMN tissues was 2.7-fold higher than that in non-neoplastic tissues, although the difference was not statistically significant \((p = 0.053)\). All data from bulk tissue analyses indicated that LMO4 was overexpressed in pancreatic cancer.

Microdissection-based quantitative analysis of LMO4 expression in IDC, PanIN-2, PanIN-1B and normal ductal cells
In general, bulk pancreatic tissues are composed of a various types of cells, including ductal epithelial, acinar, islet and mesenchymal cells, and fibroblasts. Cancer cells comprise only 30% – 70% of the cells in bulk tissue specimens of pancreatic cancer [27]. Premalignant cells, such as PanINs, and normal ductal cells comprise even smaller percentages of the cells in non-malignant tissues. The results of our present analyses of cultured cells suggested that LMO4 was expressed in pancreatic fibroblasts (Figure 3). Therefore, to avoid the influence of contaminating non-duetal cells, we used a laser-microdissection (LMD) method to select specific ductal cells for further analysis.
To investigate the involvement of LMO4 in the PanIN-IDC pathway, we isolated IDC cells from 8 lesions, PanIN-2 cells from 3 lesions, PanIN-1B cells from 14 lesions and normal ductal epithelial cells from 13 ducts by LMD (Figure 2) for quantitative analysis of LMO4 by RT-PCR. As shown in Figure 5, IDC cells expressed significantly higher levels of LMO4 than did normal ductal epithelial or PanIN-1B cells (p < 0.0001 for both) or PanIN-2 cells (p = 0.014). The mean LMO4 expression level was 2.19 (95% CI, 1.43 – 2.94) in IDC cells, 0.32 (95% CI, 0.18 – 0.45) in PanIN-2 cells, 0.41 (95% CI, 0.27 – 0.54) in PanIN-1B cells and 0.45 (95% CI, 0.30 – 0.60) in normal ductal epithelial cells. The difference in LMO4 expression between PanIN-2 and normal ductal cells or between PanIN-1B and normal ductal cells was not significant (p = 0.54 and p = 0.56, respectively). These data suggested that LMO4 is overexpressed in pancreatic cancer, especially in the invasive step of cancer, but not in the early stage of pancreatic carcinogenesis.

Quantitative analyses of LMO4 expressions in IPMC, IPMB, IPMA and normal ductal cells
To investigate the correlation of LMO4 expression with the IPMA-IPMC pathway, we microdissected IPMC cells from 5 invasive lesions and 3 non-invasive lesions (CIS), IPMB cells from 15 lesions, IPMA cells from 13 lesions and normal ductal epithelial cells from 6 ducts. We then measured LMO4 expression in these cells by qRT-PCR (Figure 2). As shown in Figure 6, IPMC cells expressed higher levels of LMO4 (mean, 1.79; 95% CI, 1.43 – 2.54) than did normal ductal cell (p < 0.0001), IPMA cells (p < 0.001) and IPMB cells (p = 0.003). There was no signifi-
Quantitative analyses of LKB1 expressions in cultured and microdissected cells, and correlation analyses between LKB1 and LMO4 in pancreatic carcinogenesis

LKB1 (also called STK11) is a tumor suppressor gene in Peutz-Jeghers syndrome [31]. Loss of this gene is found in pancreatic cancer [32,33]. Recently, LKB1 was reported to induce p21 expression in collaboration with LMO4 [34]. To investigate the potential role of LMO4 in pancreatic carcinogenesis, we measured LKB1 mRNA expression in cultured and microdissected cells and investigated any correlation between LKB1 and LMO4 expression. In the analysis of cultured cells, we found significant correlation between LKB1 and LMO4 mRNA levels in primary cultured fibroblasts (n = 6, spearman test, p = 0.024; Figure 7a, top). By contrast, there was no significant correlation between LKB1 and LMO4 mRNA levels in cultured cancer cell lines (n = 14, spearman test, p = 0.33; Figure 7a bottom). In the analysis of microdissected cells, IDC cells expressed significantly lower levels of LKB1 mRNA than did PanIN-1B or normal ductal cells (n = 12, p = 0.02; n = 8; p = 0.002, respectively; Figure 7b top). There was a significant correlation between LKB1 and LMO4 mRNA levels in non-malignant cells, including normal pancreatic ductal epithelia and PanIN-1B cells (n = 20, p = 0.042, Figure 7b middle), but no significant correlation in IDC cells (n = 8, p = 0.45, Figure 7b bottom).

Discussion

In the present study, we performed quantitative real-time RT-PCR to measure LMO4 expression during pancreatic carcinogenesis through the PanIN-IDC and IPMA-IPMC pathways. Analyses of cultured cells revealed that 9 of 14 pancreatic cancer cell lines and all primary cultures of pancreatic fibroblasts expressed higher levels of LMO4 than did PanIN-1B or normal ductal cells (n = 12, p = 0.02; n = 8; p = 0.45, respectively). There was a significant correlation between LKB1 and LMO4 mRNA levels in non-malignant cells, including normal pancreatic ductal epithelia and PanIN-1B cells (n = 20, p = 0.042, Figure 7b middle), but no significant correlation in IDC cells (n = 8, p = 0.45, Figure 7b bottom).

Figure 6

LMO4 expressions in the IPMA-IPMC pathway, including 6 normal ductal epithelial ducts, 13 IPMA lesions, 15 IPMB lesions and 8 IPMC lesions (5 for invasive IPMC and 5 for non-invasive IPMCs). IPMC cells expressed significantly higher levels of LMO4 (mean, 1.79; 95% CI, 0.99 – 2.58) than did IPMB (mean, 0.98; 95% CI, 0.69 – 1.27) (p = 0.003), IPMA (mean, 0.60; 95% CI, 0.47 – 0.73) (p < 0.001), or normal ductal epithelial cells (mean, 0.65; 95% CI, 0.34 – 0.95) (p < 0.001). The differences in LMO4 expression between IPMB and IPMA cells (p = 0.09), IPMB and normal ductal epithelial cells (p = 0.2) and IPMA and normal ductal epithelial cells (p = 0.9) are not significant. The bottom and the top edges of the box mark the lower bound and upper bound of the 95% Confidence Interval for the Mean, respectively. The center horizontal line is drawn at the sample mean. The center vertical lines drawn from the boxes extend to the minimum and the maximum. Expression of LMO4 mRNA was normalized to that of 18S rRNA.

cant difference in LMO4 expression between invasive IPMC and non-invasive IPMC (CIS). Although the mean LMO4 expression in IPMB cells (0.98; 95% CI, 0.69 – 1.27) was higher than that in IPMA (0.60; 95% CI, 0.47 – 0.73) or normal ductal cells (0.65; 95% CI, 0.34 – 0.95), the differences in LMO4 expression were not significant. Taken together, these data suggested that LMO4 expression may be up-regulated during the late stages of carcinogenesis of IPMN.
higher levels of LMO4 than did non-malignant IPMN or normal ductal cells. By contrast, we could not detect any differences in LMO4 expression among PanIN-1B, PanIN-2 and normal ductal cells, or among IPMA, IPMB, and normal ductal cells. Taken together, these data suggested that LMO4 expression is up-regulated in pancreatic cancer but not in low-grade intraductal precursors in both the PanIN-IDC and IPMA-IPMC pathways.

This is the first report to use qRT-PCR for analyses of LMO4 expression during pancreatic carcinogenesis. LMO4 is reported to have an oncogenic role in carcinogenesis and in carcinoma progression in breast cancer and SCC [18-21]. However, the human LMO4 gene is located on chromosome 1p22.3 [35], which is a region deleted in several human cancers, such as those of liver, skin, and lung [36,37], and Setogawa et al reported that the tumor suppressor LKB1 induces p21 expression in collaboration with LMO4, suggesting that LMO4 may have a tumor suppressor function [34]. In the present study, we found that there was significant correlation between LMO4 and LKB1 in both primary cultured fibroblasts and microdissected

Figure 7

Correlation analyses between LKB1 and LMO4 in pancreatic carcinogenesis. a, Correlation between LKB1 and LMO4 in primary cultured fibroblasts (spearman test, p = 0.037, top) and correlation between LKB1 and LMO4 in cultured cancer cell lines (spearman test, p = 0.39, bottom). b, Expression of LKB1 mRNA levels in microdissected normal ducts, PanIN-1B cells, and IDC cells (top). The bottom and the top edges of the box mark the lower bound and upper bound of the 95% Confidence Interval for the Mean, respectively. The center horizontal line is drawn at the sample mean. The center vertical lines drawn from the boxes extend to the minimum and the maximum. Correlation between LKB1 and LMO4 mRNA levels in non-malignant cells (including normal ducts and PanIN-1B cells, spearman test, p = 0.042, middle), and correlation between LKB1 and LMO4 mRNA levels in IDC cells (spearman test, p = 0.453, bottom). Expression of LMO4 mRNA was normalized to that of 18S rRNA.
non-malignant cells, but there was not a significant cor-
relation between \textit{LMO4} and \textit{LKB1} in cancer cells. We also
found the downregulation of \textit{LKB1} mRNA in IDC cells,
consistent with \textit{LKB1}’s tumor suppressive function. Our
data suggest that alteration of the \textit{LKB1-LMO4} balance is
involved in pancreatic carcinogenesis, although the exact
function of \textit{LMO4} in pancreatic carcinogenesis remains
unknown. Taken together, there appears to be a conflict-
ing function of \textit{LMO4} in carcinogenesis as a tumor sup-
pressor or as an oncogene; it is reasonable that \textit{LMO4}, a
transcription regulator, may have multiple functions in
individual cancers, like E2F1, an another transcription fac-
tor, that was reported both as an oncogene by stimulating
cell proliferation [38] and as a tumor suppressor by sign-
aling p53-dependent apoptosis [39].

Recently, Murphy et al [40] used immunohistochemical
staining and reported that a subset of patients with low
\textit{LMO4} expression-pancreatic cancers had poor outcomes.
In the present study, \textit{LMO4} mRNA was not overexpressed
in any of the 14 pancreatic cancer cell lines. However, all
IDC cells microdissected from cancer tissues showed rela-
tively high expression of \textit{LMO4} mRNA although the sam-
ple number was small. This might have been the result of
using of frozen sections with a histological diagnosis of
moderately or well-differentiated adenocarcinoma, which
can be microdissected easily. Patients with well-differenti-
ated adenocarcinoma usually have better prognosis [41];
thus the present data may be partially consistent with
Murphy’s result demonstrating that high \textit{LMO4}-pancre-
atic cancers are associated with a significant survival advan-
tage for patients with surgical resection.

Taken together, it remains unclear if \textit{LMO4} has an onco-
genic function or a tumor suppressive function in pancre-
atic carcinogenesis. To better clarify the functional roles of
\textit{LMO4} in pancreatic carcinogenesis, further examinations
such as inhibition experiments using RNAi technology are
needed.

In conclusion, the present results showed that \textit{LMO4}
is overexpressed in pancreatic cancer related to both the
PanIN-conventional IDC pathway and the IPMA-IPMC
pathway, but not at the early stages of pancreatic carci-
ogenesis.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JY participated in the design of the study, carried out the
RNA expression analysis, Laser Capture Microdissection
studies, statistical analysis, and drafted the manuscript.
KO and KM participated in the design and coordination of
the study, performed the statistical analysis, and critically
revised the manuscript. LC performed realtime expression
analysis and critically revised the manuscript. KN and HY
participated in histologic examination and critically revise
the manuscript. HE, TE and HK performed the statistical
analysis and critically revised the manuscript. MT planned
and coordinated the study, and critically revised the man-
uscript. All authors have read and approved the final ver-
sion of the manuscript.

Acknowledgements
We thank Miyuki Ohmori for expert technical assistance in preparing fro-
zen sections for microdissection, and thank Shoko Sadatomi, Midori Sato,
and Emiko Manabe for help in maintaining the cultures of cell line and clin-
cal samples. This work has been supported by the grants from the Ministry
of Education, Culture, Sports, Science and Technology of Japan; the Fuku-
oka Cancer Society, Pancreas Research Foundation of Japan; Clinical
Research Foundation; and Kaibara Morikazu Medical Science Promotion
Foundation. We appreciate for the technical supports from the Research
Support Center, Graduate School of Medical Sciences, Kyushu University,
Japan.

References
1. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N
Engl J Med 1992, 326:65-65.
2. Yamamoto M, Ohashi O, Saitoh Y: Japan Pancreatic Cancer Reg-
istry: current status. Pancreas 1998, 16:238-42.
3. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, et al.: Pancreatic Cancer Registry in Japan: 20 years of experience.
Pancreas 2004, 38:219-30.
4. Tanaka M: Important clues to the diagnosis of pancreatic cancer.
Roczni Akademii Medycznej w Białymstoku (1995) 2005,
50:69-72.
5. House MG, Guo M, Iacobuzio-Donahue C, Herman JG: Molecular
progression of promoter methylation in intraductal papillary mucinous
neoplasms (IPMN) of the pancreas. Carcinogenesis 2003, 24:193-8.
6. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J,
Blankin AV, et al.: An illustrated consensus on the classification of
pancreatic intraepithelial neoplasia and intraductal papillary
mucinous neoplasms. Am J Surg Pathol 2004, 28:977-87.
7. Klimstra DS, Longnecker DS: K-ras mutations in pancreatic duct-
al proliferative lesions. The American journal of pathology 1994,
145:1547-50.
8. Nakata B, Yashiro M, Nishioka N, Aya M, Yamada S, Takenaka C, et al.: Genetic alterations in adenoma-carcinoma sequencing of
intraductal papillary-mucinous neoplasm of the pancreas. Int J
Oncol 2002, 21:1067-72.
9. Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS: Intraduc-
tal papillary-mucinous neoplasms of the pancreas: an analysis
of in situ and invasive carcinomas in 28 patients. Cancer 2002,
99:52-67.
10. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES,
Goodman SN, et al.: Pancreatic intraepithelial neoplasia: a new
omenclature and classification system for pancreatic duct
lesions. Am J Surg Pathol 2001, 25:579-86.
11. Takaori K, Kobashi Y, Matsuue S, Matsui K, Yamamoto T: Clinic-
opathological features of pancreatic intraepithelial neoplasia and
their relationship to intraductal papillary-mucinous tumors. J Hepatobiliary Pancreat Surg 2003, 10:125-36.
12. Longnecker DS, Adsay NV, Fernandez-del Castillo C, Hruban RH,
Kasuga T, Klimstra DS, et al.: Histopathological diagnosis of pan-
creatic intraepithelial neoplasia and intraductal papillary-
mucinous neoplasms: interobserver agreement. Pancreas 2005,
31:344-9.
13. Kenny DA, Jurata LW, Saga Y, Gill GN: Identification and charac-
terization of LMO4, an LMO gene with a novel pattern of
expression during embryogenesis. Proc Natl Acad Sci USA 1998,
95:1257-62.
14. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbits TH: The rhom-
botin family of cysteine-rich LIM-domain oncogenes: distinct
members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 1991, 88:4367-71.

15. Rovery-Pokora B, Loos U, Ludwig WD: TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 1991, 6:1887-93.

16. Lu Z, Lam KS, Wang N, Xu X, Cortes M, Andersen B: LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells. Oncogene 2006, 25:2920-30.

17. Racevskis J, Dill A, Sparano JA, Ruan H: Molecular cloning of LMO4, a new human LIM domain gene. Biochim Biophys Acta 1999, 1445:48-53.

18. Vsvader JE, Venter D, Hahn K, Santamaria M, Sum EY, O'Reilly L, et al.: The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in normal breast tissue. Proc Natl Acad Sci USA 2001, 98:14452-7.

19. Sum EY, Peng B, Yu X, Chen J, Byrne J, Lindeman GJ, et al.: The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. J Biol Chem 2002, 277:7849-56.

20. Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, et al. Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci USA 2005, 102:7659-64.

21. Mizunuma H, Physawa J, Sanada K, Imai K. The LIM-only protein, LMO4, and the LIM domain-binding protein, LDB1, expression in squamous cell carcinomas of the oral cavity. British journal of cancer 2003, 88:1543-8.

22. Wang N, Lin KK, Lu Z, Lam KS, Newton R, Xu X, et al.: The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells. Oncogene 2007, 26:6431-41.

23. Kitamura N, Murata S, Abe H, Hanawasa K, Tsukashita S, Tani T: Obstructive jaundice in a metastatic tumor of the pancreas from breast cancer: a case report. Japanese journal of clinical oncology 2003, 33:93-97.

24. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, et al.: DPC4 gene in various tumor types. Cancer research 1996, 56:2527-30.

25. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Naga E, et al.: Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer research 2004, 64:3215-22.

26. Yu J, Ohuchida K, Mochizuki K, Ishikawa N, Ogura Y, Yamada D, et al.: Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol 2006, 12:3878-82.

27. Changcze F, Pachir N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical biochemistry 1987, 162:156-9.

28. Tachikawa T, Irie T: A new molecular biology approach in morpholgy: basic method and application of laser microdissection. Med Electron Microsc 2004, 37:83.

29. Liu N, Furukawa T, Kobari M, Tosa MS: Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. The American journal of pathology 1998, 153:263-9.

30. Xu GH, Hruban RH, Bansal RK, Bova GS, Tang D, Shekher MC, et al.: Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. The American journal of pathology 1999, 154:1835-40.

31. Setogawa T, Shinozaki-Yabana S, Masuda T, Matsuura K, Akiyama T: The tumor suppressor LKB1 induces p21 expression in collaboration with LMO4, GATA-4, and Ldb1. Biochemical and biophysical research communications 2006, 343:1186-90.

32. Sato N, Rosty C, Jansen M, Fukushima N, Ueki T, Yeo CJ, et al.: STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. The American journal of pathology 2001, 159:2017-22.

33. Tse E, Gruetz G, Garner AA, Ramsey Y, Carter NP, Copeland N, et al.: Characterization of the Lmo4 gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping. Mamm Genome 1999, 10:1089-94.

34. Singh P, Hong W: Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. The EMBO journal 1994, 13:3293-30.